{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T07:24:03Z","timestamp":1772609043413,"version":"3.50.1"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T00:00:00Z","timestamp":1758412800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology - Research and Practice"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.prp.2025.156240","type":"journal-article","created":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T22:18:47Z","timestamp":1758579527000},"page":"156240","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["A subgroup of anaplastic thyroid carcinomas harbors MET alterations with potential therapeutic options"],"prefix":"10.1016","volume":"275","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2704-6469","authenticated-orcid":false,"given":"Sarah","family":"Theurer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans-Ulrich","family":"Schildhaus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Herold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tim","family":"Brandenburg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dagmar","family":"F\u00fchrer-Sakel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideo Andreas","family":"Baba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Ingenwerth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabrina","family":"Borchert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.prp.2025.156240_bib1","unstructured":"A.K. El-Naggar, Z.W. Baloch, C. Eng, Anaplastic Thyroid Carcinoma, in Who Classification of Endocrine Organs. Lloyd R. V. Osamura R. Y. Kl. \u00f6ppel G. Rosai J.2017, 104106."},{"key":"10.1016\/j.prp.2025.156240_bib2","article-title":"Coexisting well-differentiated and anaplastic thyroid carcinoma in the same primary resection specimen: immunophenotypic and genetic comparison of the two components in a consecutive series of 13 cases and a review of the literature","author":"Ragazzi","year":"2020","journal-title":"Virchows Arch."},{"issue":"1","key":"10.1016\/j.prp.2025.156240_bib3","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.21037\/gs.2019.10.18","article-title":"Novel treatments for anaplastic thyroid carcinoma","volume":"9","author":"Ferrari","year":"2020","journal-title":"Gland Surg."},{"issue":"12","key":"10.1016\/j.prp.2025.156240_bib4","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1002\/(SICI)1097-0142(19981215)83:12<2638::AID-CNCR31>3.0.CO;2-1","article-title":"A national cancer data base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995 [see commetns]","volume":"83","author":"Hundahl","year":"1998","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.prp.2025.156240_bib5","doi-asserted-by":"crossref","first-page":"R153","DOI":"10.1530\/ERC-17-0435","article-title":"Anaplastic thyroid carcinoma: review of treatment protocols","volume":"25","author":"Tiedje","year":"2018","journal-title":"Endocr. Relat. Cancer"},{"issue":"17","key":"10.1016\/j.prp.2025.156240_bib6","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1002\/cncr.28187","article-title":"Marginal treatment benefit in anaplastic thyroid cancer","volume":"119","author":"Haymart","year":"2013","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.prp.2025.156240_bib7","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1385\/EP:12:2:157","article-title":"Paucicellular variant of anaplastic thyroid carcinoma: report of two cases","volume":"12","author":"Canos","year":"2001","journal-title":"Endocr. Pathol."},{"issue":"26","key":"10.1016\/j.prp.2025.156240_bib8","doi-asserted-by":"crossref","first-page":"42613","DOI":"10.18632\/oncotarget.17300","article-title":"NGS based identification of mutational hotspots for targeted therapy in anaplastic thyroid carcinoma","volume":"8","author":"Tiedje","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.prp.2025.156240_bib9","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1186\/s12885-015-1955-9","article-title":"The genomic and transcriptomic landscape of anaplastic thyroid cancer: implications for therapy","volume":"15","author":"Kasaian","year":"2015","journal-title":"BMC Cancer"},{"issue":"11","key":"10.1016\/j.prp.2025.156240_bib10","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1089\/thy.2012.0302","article-title":"American thyroid association guidelines for management of patients with anaplastic thyroid cancer","volume":"22","author":"Smallridge","year":"2012","journal-title":"Thyroid"},{"issue":"11","key":"10.1016\/j.prp.2025.156240_bib11","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1038\/nrendo.2017.76","article-title":"Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies","volume":"13","author":"Molinaro","year":"2017","journal-title":"Nat. Rev. Endocrinol."},{"issue":"4","key":"10.1016\/j.prp.2025.156240_bib12","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1158\/1078-0432.CCR-14-0450","article-title":"MET amplification status in therapy-naive adeno- and squamous cell carcinomas of the lung","volume":"21","author":"Schildhaus","year":"2015","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.prp.2025.156240_bib13","doi-asserted-by":"crossref","first-page":"603","DOI":"10.21037\/tlcr-19-339","article-title":"Top-level MET gene copy number gain defines a subtype of poorly differentiated pulmonary adenocarcinomas with poor prognosis","volume":"9","author":"Overbeck","year":"2020","journal-title":"Transl. Lung Cancer Res."},{"issue":"2","key":"10.1016\/j.prp.2025.156240_bib14","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1530\/EJE-20-0080","article-title":"Anaplastic thyroid carcinoma: a nationwide cohort study on incidence, treatment and survival in the Netherlands over 3 decades","volume":"183","author":"de Ridder","year":"2020","journal-title":"Eur. J. Endocrinol."},{"issue":"10","key":"10.1016\/j.prp.2025.156240_bib15","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1056\/NEJMoa2002787","article-title":"Capmatinib in MET exon 14-mutated or MET-amplified non-small-cell lung cancer","volume":"383","author":"Wolf","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.prp.2025.156240_bib16","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1089\/thy.2016.0254","article-title":"Molecular pathology of anaplastic thyroid carcinomas: a retrospective study of 144 cases","volume":"27","author":"Bonhomme","year":"2017","journal-title":"Thyroid"},{"issue":"D1","key":"10.1016\/j.prp.2025.156240_bib17","doi-asserted-by":"crossref","first-page":"D1062","DOI":"10.1093\/nar\/gkx1153","article-title":"ClinVar: improving access to variant interpretations and supporting evidence","volume":"46","author":"Landrum","year":"2018","journal-title":"Nucleic Acids Res."},{"issue":"4","key":"10.1016\/j.prp.2025.156240_bib18","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/nmeth.2890","article-title":"MutationTaster2: mutation prediction for the deep-sequencing age","volume":"11","author":"Schwarz","year":"2014","journal-title":"Nat. Methods"},{"key":"10.1016\/j.prp.2025.156240_bib19","doi-asserted-by":"crossref","DOI":"10.1089\/thy.2019.0802","article-title":"RET, NTRK, ALK, BRAF, and MET fusions in a large cohort of pediatric papillary thyroid carcinomas","author":"Pekova","year":"2020","journal-title":"Thyroid"},{"issue":"9","key":"10.1016\/j.prp.2025.156240_bib20","doi-asserted-by":"crossref","DOI":"10.3390\/genes10090709","article-title":"Molecular alterations in thyroid cancer: from bench to clinical practice","volume":"10","author":"Tirro","year":"2019","journal-title":"Genes"},{"issue":"3","key":"10.1016\/j.prp.2025.156240_bib21","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/nrc3431","article-title":"Molecular pathogenesis and mechanisms of thyroid cancer","volume":"13","author":"Xing","year":"2013","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.prp.2025.156240_bib22","doi-asserted-by":"crossref","first-page":"18657","DOI":"10.1038\/srep18657","article-title":"Novel kinase fusion transcripts found in endometrial cancer","volume":"5","author":"Tamura","year":"2015","journal-title":"Sci. Rep."},{"issue":"D1","key":"10.1016\/j.prp.2025.156240_bib23","doi-asserted-by":"crossref","first-page":"D1144","DOI":"10.1093\/nar\/gkx1018","article-title":"TumorFusions: an integrative resource for cancer-associated transcript fusions","volume":"46","author":"Hu","year":"2018","journal-title":"Nucleic Acids Res."},{"issue":"6","key":"10.1016\/j.prp.2025.156240_bib24","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/ng.3564","article-title":"Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas","volume":"48","author":"Campbell","year":"2016","journal-title":"Nat. Genet."},{"issue":"8","key":"10.1016\/j.prp.2025.156240_bib25","first-page":"10983","article-title":"Tumor heterogeneity with novel MET fusion showed different response to cabozantinib in non-small cell lung cancer","volume":"12","author":"Lanfang Yu","year":"2019","journal-title":"Int. J. Clin. Exp. Med."},{"issue":"8","key":"10.1016\/j.prp.2025.156240_bib26","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1097\/PAS.0000000000001065","article-title":"Salivary secretory carcinoma with a novel ETV6-MET fusion: expanding the molecular spectrum of a recently described entity","volume":"42","author":"Rooper","year":"2018","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.prp.2025.156240_bib27","doi-asserted-by":"crossref","DOI":"10.1634\/theoncologist.2020-0502","article-title":"Tepotinib efficacy in an NSCLC patient with brain metastasis harboring an HLA-DRB1-MET gene fusion","author":"Blanc-Durand","year":"2020","journal-title":"Oncologist"},{"issue":"6","key":"10.1016\/j.prp.2025.156240_bib28","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1158\/1078-0432.CCR-17-3001","article-title":"Structural alterations of MET trigger response to MET kinase inhibition in lung adenocarcinoma patients","volume":"24","author":"Plenker","year":"2018","journal-title":"Clin. Cancer Res."},{"issue":"8","key":"10.1016\/j.prp.2025.156240_bib29","doi-asserted-by":"crossref","first-page":"3106","DOI":"10.1210\/jc.2008-0273","article-title":"Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase\/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers","volume":"93","author":"Liu","year":"2008","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"6","key":"10.1016\/j.prp.2025.156240_bib30","doi-asserted-by":"crossref","first-page":"e126","DOI":"10.1016\/j.jtho.2019.01.025","article-title":"A novel CAV1-MET fusion in SCLC transformation responds to crizotinib and osimertinib treatment","volume":"14","author":"Liu","year":"2019","journal-title":"J. Thorac. Oncol."},{"issue":"12","key":"10.1016\/j.prp.2025.156240_bib31","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1089\/thy.2019.0802","article-title":"RET, NTRK, ALK, BRAF, and MET fusions in a large cohort of pediatric papillary thyroid carcinomas","volume":"30","author":"Pekova","year":"2020","journal-title":"Thyroid"},{"issue":"5","key":"10.1016\/j.prp.2025.156240_bib32","doi-asserted-by":"crossref","DOI":"10.1101\/mcs.a005645","article-title":"Infantile fibrosarcoma-like tumor driven by novel RBPMS-MET fusion consolidated with cabozantinib","volume":"6","author":"Gupta","year":"2020","journal-title":"Cold Spring Harb. Mol. Case Stud."},{"key":"10.1016\/j.prp.2025.156240_bib33","doi-asserted-by":"crossref","DOI":"10.1634\/theoncologist.2020-0535","article-title":"Identification of a novel EHBP1-MET fusion in an intrahepatic cholangiocarcinoma responding to crizotinib","author":"Yu","year":"2020","journal-title":"Oncologist"},{"issue":"8","key":"10.1016\/j.prp.2025.156240_bib34","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.neo.2018.06.007","article-title":"Oncogenic function of a KIF5B-MET fusion variant in Non-Small cell lung cancer","volume":"20","author":"Gow","year":"2018","journal-title":"Neoplasia"},{"issue":"11","key":"10.1016\/j.prp.2025.156240_bib35","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1038\/nm.4204","article-title":"International cancer genome consortium PedBrain tumor, P., recurrent met fusion genes represent a drug target in pediatric glioblastoma.","volume":"22","year":"2016","journal-title":"Nat. Med."},{"issue":"11","key":"10.1016\/j.prp.2025.156240_bib36","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1101\/gr.165126.113","article-title":"RNA-seq of 272 gliomas revealed a novel, recurrent PTPRZ1-MET fusion transcript in secondary glioblastomas","volume":"24","author":"Bao","year":"2014","journal-title":"Genome Res."},{"key":"10.1016\/j.prp.2025.156240_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114306","article-title":"Benchmarking whole exome sequencing in the German network for personalized Medicine","author":"Menzel","year":"2024","journal-title":"Eur. J. Cancer"},{"issue":"3","key":"10.1016\/j.prp.2025.156240_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.113826","article-title":"The genomic and evolutionary landscapes of anaplastic thyroid carcinoma","volume":"43","author":"Zeng","year":"2024","journal-title":"Cell Rep."},{"issue":"23","key":"10.1016\/j.prp.2025.156240_bib39","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.18632\/oncotarget.26798","article-title":"MET overexpression and activation favors invasiveness in a model of anaplastic thyroid cancer","volume":"10","author":"Garcia","year":"2019","journal-title":"Oncotarget"},{"issue":"10","key":"10.1016\/j.prp.2025.156240_bib40","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1158\/1078-0432.CCR-18-2953","article-title":"Comprehensive genetic characterization of human thyroid cancer cell lines: a validated panel for preclinical studies","volume":"25","author":"Landa","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"9","key":"10.1016\/j.prp.2025.156240_bib41","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/s41571-020-0377-z","article-title":"MET-dependent solid tumours - molecular diagnosis and targeted therapy","volume":"17","author":"Guo","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.prp.2025.156240_bib42","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1158\/1078-0432.CCR-21-1566","article-title":"FDA approval summary: capmatinib and tepotinib for the treatment of metastatic NSCLC harboring MET exon 14 skipping mutations or alterations","volume":"28","author":"Mathieu","year":"2022","journal-title":"Clin. Cancer Res."}],"container-title":["Pathology - Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033825004339?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033825004339?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T22:39:34Z","timestamp":1762295974000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0344033825004339"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":42,"alternative-id":["S0344033825004339"],"URL":"https:\/\/doi.org\/10.1016\/j.prp.2025.156240","relation":{},"ISSN":["0344-0338"],"issn-type":[{"value":"0344-0338","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A subgroup of anaplastic thyroid carcinomas harbors MET alterations with potential therapeutic options","name":"articletitle","label":"Article Title"},{"value":"Pathology - Research and Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prp.2025.156240","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier GmbH.","name":"copyright","label":"Copyright"}],"article-number":"156240"}}